Featured Research

from universities, journals, and other organizations

Development Of New Polymer Delivery Vehicles For Gene Therapy

Date:
October 17, 2006
Source:
American Chemical Society
Summary:
MIT scientists are reporting synthesis and laboratory tests of a promising new group of degradable polymer delivery vehicles for gene therapy. The polymers are improved versions of materials first described in 2000 that deliver genes efficiently to specific cells.

MIT scientists are reporting synthesis and laboratory tests of a promising new group of degradable polymer delivery vehicles for gene therapy. The polymers are improved versions of materials first described in 2000 that deliver genes efficiently to specific cells.

The lack of a safe, efficient delivery system for DNA has been a major barrier to clinical use of gene therapy. Viruses and various polymer materials have been used in efforts to insert therapeutic genes into diseased cells. However, those systems have disadvantages. Some of the polymer materials, for instance, insert genes into only a small percentage of cells and do not degrade in the body.

Robert Langer and colleagues used laboratory experiments to show that the polymers can deliver DNA to human liver cancer cells. Their report is scheduled for the current (Oct. 15) issue of the weekly Journal of the American Chemical Society.

One polymer has potential for carrying genes to the supply of tiny blood vessels that enables cancer cells to grow and spread. "We are currently testing the targeting effects of this polymer on endothelial cells, and it is envisioned that this delivery system could permit localization and transfection of the tumor vasculature for cancer therapies," the report states.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Development Of New Polymer Delivery Vehicles For Gene Therapy." ScienceDaily. ScienceDaily, 17 October 2006. <www.sciencedaily.com/releases/2006/10/061016121908.htm>.
American Chemical Society. (2006, October 17). Development Of New Polymer Delivery Vehicles For Gene Therapy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/10/061016121908.htm
American Chemical Society. "Development Of New Polymer Delivery Vehicles For Gene Therapy." ScienceDaily. www.sciencedaily.com/releases/2006/10/061016121908.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins